Physician profile
Arvind Kumar
NPI 1356357479
$7,225.22
in general payments reported to CMS, 2019-2025
56 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $738 · 2021: $1,232 · 2022: $1,198 · 2023: $1,031 · 2024: $1,000 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,842 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,842.03 |
| Education | $293.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $927.27 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Amgen INC. | $821.99 | 2019-2023 | Vectibix, Xgeva, Nplate |
| E.R. Squibb & Sons, L.L.C. | $429.93 | 2019-2025 | Opdualag, Opdivo, Krazati |
| Astrazeneca Pharmaceuticals Lp | $380.14 | 2019-2025 | Tagrisso |
| Novartis Pharmaceuticals Corporation | $347.62 | 2019-2025 | |
| Incyte Corporation | $304.01 | 2019-2025 | Jakafi |
| Glaxosmithkline, LLC. | $265.00 | 2021-2025 | Arexvy, Zejula, Jemperli |
| Pfizer INC. | $255.26 | 2019-2025 | |
| Daiichi Sankyo INC. | $250.06 | 2019-2025 | Injectafer |
| Seagen INC. | $230.40 | 2020-2024 | Padcev, Tukysa |
| Astellas Pharma US INC | $211.37 | 2019-2024 | Xtandi, Padcev |
| Eisai INC. | $180.01 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $173.86 | 2022-2025 | Monoferric |
| Merck Sharp & Dohme LLC | $161.80 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.53 | 2020-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $139.24 | 2019-2023 | Opdualag |
| Janssen Pharmaceuticals, INC | $133.48 | 2019-2021 | |
| Gilead Sciences, INC. | $128.19 | 2022-2023 | Trodelvy |
| Kowa Pharmaceuticals America, INC. | $124.98 | 2022 | |
| Novo Nordisk INC | $124.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.19 | 2021 | |
| Coherus Oncology, INC. | $108.11 | 2022-2023 | |
| Lilly USA, LLC | $105.43 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Array Biopharma INC | $98.86 | 2021-2025 | Braftovi, Tukysa, Mektovi |
| Regeneron Healthcare Solutions, INC. | $88.65 | 2023-2025 | Libtayo |
| Exelixis INC. | $74.56 | 2022-2024 | Cabometyx |
| Emd Serono, INC. | $62.62 | 2023-2024 | Tepmetko, Bavencio |
| Ipsen Biopharmaceuticals, INC | $62.38 | 2025 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $54.19 | 2022-2025 | Iclusig, Ninlaro |
| Genentech USA, INC. | $52.39 | 2019-2025 | Venclexta |
| Taiho Oncology, INC. | $52.05 | 2024-2025 | |
| Puma Biotechnology, INC. | $49.50 | 2024-2025 | |
| Abbvie INC. | $48.51 | 2023-2025 | |
| Geron Corporation | $48.12 | 2025 | Rytelo |
| Tempus Ai, INC | $44.80 | 2024-2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $40.11 | 2022-2023 | Clonoseq |
| Dendreon Pharmaceuticals LLC | $38.75 | 2024 | Provenge |
| Aveo Pharmaceuticals, INC. | $36.67 | 2022-2023 | Fotivda |
| Octapharma USA, INC. | $33.76 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Rigel Pharmaceuticals, INC. | $25.84 | 2022 | |
| Lundbeck LLC | $18.87 | 2024 | Vyepti |
| Invivyd INC | $18.68 | 2025 | Pemgarda |
| Blueprint Medicines Corporation | $18.31 | 2024 | Ayvakit |
| Sobi, INC | $17.76 | 2025 | |
| Apellis Pharmaceuticals, INC. | $16.57 | 2023 | Empaveli |
| Acrotech Biopharma INC. | $16.56 | 2024 | Ryzneuta |
| Pharmaessentia USA Corporation | $16.38 | 2025 | Besremi |
| Foundation Medicine, INC. | $15.83 | 2020 | |
| Dova Pharmaceuticals | $14.93 | 2020 | |
| Sumitomo Pharma America, INC. | $14.65 | 2025 | Orgovyx |
| Tesaro, INC. | $14.43 | 2019 | |
| Heron Therapeutics, INC. | $14.20 | 2022 | |
| Acceleron Pharma, INC. | $13.83 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $13.81 | 2019 | |
| Karyopharm Therapeutics INC. | $12.76 | 2022 | |
| Global Blood Therapeutics, INC. | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.